Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
Oral CGRP Inhibitor Is First For Dual Use
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.
